The CEA-CD3 bispecific T-cell engager was pitched as a treatment for colorectal cancer but looks to have failed in early-phase trials.
Accent is working to understand which RNA-modifying proteins are involved in which cancer indications, and to develop drugs to target them.
Implementation guidelines to support GxP in the cloud
Takeda's plan involves signing on one or more large, long-term investors, as well as keeping its R&D pipeline alive by discarding programs that don…
Seattle Genetics appointed Roger Dansey as CMO, who led Merck’s late-stage oncology work, including developing Keytruda in multiple tumor types.
For children diagnosed with rare diseases, traditional drug development timelines are not good enough. Collaborative partnerships are imperative to accelerate…
The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Scientists at Duke have identified a pathway in the liver that they believe could be manipulated to reduce the deposition of fat in the liver, as well as…
Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.
In our EuroBiotech roundup this week, European biotechs raise more than $240 million in a flurry of public and private financings.
In this week's EuroBiotech Report, Bluebird and Medigene expand their TCR pact, Novo pushes into stem cell therapies, MeiraGTx files for IPO and more.
With the diabetes project moving to within a few years of the clinic, Novo is stepping up its interest in stem cell therapies more broadly.